![Kolon TissueGene co-CEO Noh Moon-jong explains the results of phase 3 clinical trials in the TG-C United States at a press conference held at Kolon One & Only Tower in Gangseo-gu, Seoul on the 21st. [Yonhap News]](https://wimg.mk.co.kr/news/cms/202607/21/rcv.YNA.20260721.PYH2026072106420001300_P1.jpg)
The stock price fell to the price limit on the news that Kolon TissueGene did not get the expected results from the U.S. phase 3 clinical trial of its osteoarthritis treatment. Kolon Life Sciences, the parent company, also plunged, greatly shrinking investor sentiment.
As of 11:15 a.m. on the 21st, Kolon TissueGene is trading at 42,900 won on the KOSDAQ market, down 18,300 won (29.90%) from the previous day.
The stock has not recovered from the fall after going…
